Top Markets
Coin of the day
Sesen Bio, Inc. Sesen Bio, Inc.

Sesen Bio, Inc.

SESN
株式のランク #34231
Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the... Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
株価
$0.6288
最終同期: 2023-03-07
時価総額
$6.00M
変化(1日)
7.29%
変化(1年)
0.00%
US
取引 Sesen Bio, Inc. (SESN)

カテゴリー

Sesen Bio, Inc.(SESN)の株式分割履歴
Sesen Bio, Inc.株(シンボル:SESN)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 17, 2026に行われました。
Aug 17, 2026より前に購入されたSESN株は、現在0SESN株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE